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 Every day in America, 90 individuals die from overdosing on prescription pain relievers 
or synthetic opioids. From 1999 to 2015, American deaths from opioid drug overdoses increased 
from 8,048 to 33,091 (National Institute on Drug Abuse, 2017). Approximately two million 
Americans in 2015 abused prescription pain relievers, which increased from 2014. Opioid 
receptors reside in the reward pathway of the brain, releasing the neurotransmitter dopamine, 
providing users with euphoria and analgesia. Long term drug use induces chronic constipation, 
drug tolerance, immune suppression, hormonal changes, and increased sensitivity to pain 
(Dennis, B., Naji, L., et al., 2014). Opioid use disorders also negatively impact an individual’s 
mental status, increasing incidences of depression, anxiety, and suicide. 
 
 This review examines previous research to assess the physiological effects of opioid 
dependence and overdose, with analysis of treatment. For treatment of opioid dependence, 
Methadone and Suboxone are useful medications. The medications provide enough opioid 
receptor activity to avoid withdrawals, but not enough stimulation compared to prescription or 
synthetic opioids. Since Methadone and Suboxone reduce activity at the opioid receptors, the 
individual experiences less physical dependence. An additional medication can be used for acute 
overdoses; Naloxone, commonly known as Narcan, can rapidly reverse an acute opioid overdose 
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Treatment of Opioid Dependence and Overdose 
Introduction 
Every day in America, 90 individuals die from overdosing on prescription pain relievers 
or synthetic opioids, compounds used for pain relief and anesthesia. Opioid receptors reside in 
the reward pathway of the brain, providing users with euphoria and analgesia. The misuse of 
opioids steadily increased from 1999 to 2015. Chronic use of opioids leads to dependence and 
affects an individual physically and mentally. Long term drug use induces chronic constipation, 
tolerance, immune suppression, hormonal change, and hyperalgesia (Dennis, B., Naji, L., et al., 
2014). Opioid use disorders also negatively impact an individual’s mental status, increasing 
incidences of depression, anxiety, and suicide (Ashrafioun, L., Bishop, T., et al., 2017) (Hassan, 
A., Howe, A., et al, 2017). With an acute opioid overdose, Naloxone is used to counter the 
effects of the opioid and increase a patient’s chance for survival. Methadone and Suboxone are 
medications available for treatment of opioid dependence. These medications elicit effects in the 
body similar to opioids to avoid withdrawals, and help the patient stop abusing the drugs. This 
review examines previous research to assess the physiological effects of opioid dependence and 
overdose, with analysis of treatment.  
 
Severity of the Opioid Epidemic 
In the early ‘90s, providers prescribed opioids at large rates, not fully aware of the severe 
consequences due to pharmaceutical companies’ assurance that these newer medications were 
not addictive. Before long, there was an epidemic of opioid misuse, leading to highly addicted 
users. Since then, overdose rates steadily increased every year (Figure 1 from the National 
Institute on Drug Abuse). For example, from 1999 to 2015, American deaths from opioid drug 
overdoses increased from 8,048 to 33,091 (National Institute on Drug Abuse, 2017). 
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Deaths from opioid overdoses in America from 1999 to 2015
 
Figure 1: The graph provided by the National Institute on Drug Abuse illustrates the significant rise of American 
deaths as the result of opioid overdose. 
 
Approximately two million Americans in 2015 abused prescription pain relievers, which 
increased from 2014. Heroin use also increased during this period, from 435,000 to 
approximately 591,000 Americans (Busch, S., Fiellin, D., et al., 2014). 21-29% of patients 
prescribed opioids for chronic pain misuse the medications, and 8-12% develop an opioid use 
disorder. Approximately 80% of people who use heroin, first misused prescription opioids 
(National Institute on Drug Abuse, 2017). To avoid escalation of the opioid epidemic, 
researchers study the cellular effects of opioids to better understand treatment options for opioid 
dependence and overdose.  
 
Cellular Mechanism of Opioids 
The movement of calcium is a key component in the cellular mechanism of opioids. After 
ingestion or injection of the drug, the opioid molecule binds to a G-protein coupled receptor 
(GPCR), either mu, delta, or kappa receptors (specific activation of each receptor will be 
discussed below). Binding of the ligand to the GPCR elicits a conformational change, which 
activates a G-protein inside the cell composed of three subunits: alpha, beta, and gamma. During 
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this activation, the molecule guanosine triphosphate (GTP) binds to the alpha subunit of the G 
protein, and the unit dissociates from the beta and gamma subunits. This GTP-activated alpha 
subunit, activates the membrane bound enzyme phospholipase C (PLC). PLC catalyzes 
hydrolysis of membrane bound phosphatidylinositol 4,5-diphosphate (PIP2), which forms two 
second messengers: diacylglyceride (DAG) and inositol 1,4,5-triphosphate (IP3) (Salaun, C., 
James, D., and Chamberlain, L., 2004) (Jin, W., Lee, N., et al., 1994).  
In the presence of calcium, DAG binds and activates protein kinase C, which then 
phosphorylates cellular proteins. This process is important for signal transduction to the nucleus. 
IP3 diffuses to the endoplasmic reticulum (ER), where its own receptors reside. The activation of 
the IP3 receptor on the endoplasmic reticulum, results in calcium moving out of the ER and into 
the cell, increasing the intracellular concentration of calcium. Calcium serves as an important 
second messenger for exocytosis, an energy-dependent process used to transport molecules out 
of a cell. The second messenger calcium also binds to calmodulin, a multifunctional protein. 
Activation of calmodulin increases enzyme activation and intracellular processes, including 
mRNA activation (Salaun, C., James, D., and Chamberlain, L., 2004). 
Calcium influx into the cell initiates release of the neurotransmitter dopamine into the 
synaptic cleft, between the two neurons (Figure 2). As stated above, calcium is important for the 
process of exocytosis. The release of a neurotransmitter is accomplished via the docking of 
vesicles to the plasma membrane. The vesicle carrying neurotransmitters fuses with the 
presynaptic membrane via the interaction of SNARE (soluble N-ethylmaleimide-sensitive factor 
attachment protein receptors) proteins on the intracellular and extracellular membranes of the 
presynaptic cell. The fusion between the vesicle and plasma membrane results in the release of 
the neurotransmitter into the synaptic cleft, and the vesicle membrane becomes part of the 
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plasma membrane (Figure 2, Neher, E. and Sakaba, T., 2008). Once dopamine is released into 
the synaptic cleft, it binds to receptors on the post-synaptic neuron, eliciting a response of 
pleasure, reward, and motivation. 
Communication between Neurons 
 
Figure 2: The process of communication between neurons with the influx of calcium, resulting in the release of 
neurotransmitters. Neurotransmitters bind to receptors on the post-synaptic neuron, eliciting a cellular response. 
 
Opioid Receptors 
Opioid receptors consist of three GPCR subtypes: mu, delta, and kappa opioid receptors. 
All three receptors are found in components of the reward pathway, including the ventral 
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Reward Pathway 
 
Figure 3: The reward pathway starting in the VTA, projecting to the nucleus accumbens, which propagates signals to 
the prefrontal cortex (National Institute on Drug Abuse, 2007). 
 
Rich in dopaminergic neurons, activation of the reward pathway stimulates feelings of 
reward, motivation, and behavior. The VTA is a dopamine-rich nucleus that projects 
dopaminergic neurons, throughout the brain, primarily to the nucleus accumbens. From the 
nucleus accumbens, the signal is propagated to the prefrontal cortex which is responsible for 
complex cognitive behavior, personality expression, decision making, and moderating social 
behavior (Adinoff, B., 2004). Natural rewards such as food and sex—as well as substances 
including alcohol, caffeine, nicotine, opioids, amphetamine, cocaine, and marijuana—increase 
the extracellular concentration of dopamine (Adinoff, B., 2004). 
Molecules that bind to these opioid receptors may be an agonist, a substance that binds to 
the receptor and elicits a response, or an antagonist which binds to the receptor and does not 
elicit a response, therefore, blocking other substances from binding. Additionally, two subtypes 
of agonists exist: endogenous or exogenous. An endogenous compound is made naturally within 
the body, including neurotransmitters and hormones. Exogenous compounds originate outside of 
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the body, but can be active inside the body, including drugs (Dhawan, B., Cesselin, F., et al., 
1996). 
Mu receptors 
Mu receptors reside in the dorsal horn of the spinal cord, periaqueductal grey of the 
brainstem, thalamus, and cortex, many of which are situated within the reward pathway of the 
brain. Beta endorphins, defined as endogenous opioid neuropeptides and peptide hormones, are 
released during exercise, pain, and stress. These substances have a high affinity for mu opioid 
receptors. Additionally, the exogenous drug Morphine has the highest affinity for mu receptors. 
Both beta endorphins and Morphine activate the mu receptors, eliciting an effect of reduced pain 
management, respiratory depression due to decreased response to carbon dioxide levels, 
euphoria, sedation, decreased GI motility (resulting in constipation), and miosis (constriction of 
pupils) (Dhawan, B., Cesselin, F., et al., 1996). 
Delta receptors 
Delta opioid receptors derive from the olfactory bulb, cerebral cortex, nucleus 
accumbens, amygdala, and pontine nucleus. Enkephalins, which are endogenous opioid 
pentapeptides, have the highest affinity for delta receptors. Enkephalins are involved in pain 
perception, movement, mood, behavior, and neuroendocrine regulation. DPDE (D-Pen 2,5 
enkephalin), an exogenous substance, also has a high affinity for the delta receptors. DPDE is 
used for research purposes only. After activation of the delta receptor, the body experiences 
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Kappa receptors 
Kappa receptors are found in the limbic system, hypothalamus, periaqueductal grey of the 
brainstem, and spinal cord. The endogenous peptide, dynorphin, has the highest affinity for the 
kappa receptors. Ketazocine, an exogenous drug used for research, has a high affinity for the 
kappa receptors, as well. Upon activation of the kappa receptors, users may experience spinal 
analgesia and inhibition of ADH (antidiuretic hormone) release. Users also experience 
hallucinations, dysphoria, overwhelming sense of dissatisfaction, anxiety, or restlessness. These 
receptors are the basis for research surrounding the mental effects of opioid use including, 
anxiety, depression, and suicide (Gannon, R., and Terrian D., 1992) (Dhawan, B., Cesselin, F., et 
al., 1996). 
 
Activation of reward pathway 
The stimulants cocaine and amphetamine directly amplify the dopaminergic signal at the 
postsynaptic dopamine receptor. Cocaine increases synaptic dopamine concentrations by 
blocking the presynaptic dopamine transporter (Figure 4). The dopamine transporter is 
responsible for reabsorbing dopamine back into the presynaptic neuron. Cocaine binds to the 
dopamine reuptake transporter, preventing the reuptake of dopamine. The synaptic concentration 
of dopamine increases, and dopamine continues to bind to the dopamine receptors on the post-
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Cocaine Mechanism of Action 
 
Figure 4: Cocaine (green) binds to the dopamine transporter (dark red), preventing the re-uptake of dopamine 
(orange) therefore, the synaptic concentration of dopamine increases, and continues to bind to the dopamine 
receptors (blue) on the post-synaptic neuron (National Institute on Drug Abuse, 2007). 
 
The amphetamines increase synaptic dopamine primarily by increasing dopamine release from 
the synaptic vesicles. Cocaine and the amphetamines increase both the absolute concentration of 
dopamine in the synapse and the time interval that dopamine remains at the post-synaptic 
receptor site (Adinoff, B., 2004). 
Various drugs activate the reward pathway indirectly via G-protein coupled receptors. 
Marijuana (THC), caffeine, and opioids activate G-protein coupled receptors by either acting as 
an agonist or antagonist. Marijuana acts as an agonist at cannabinoid receptors and caffeine 
activates the pathway as an antagonist at striatal adenosine A2 receptors. Opioids, such as heroin 
and morphine, activate G-protein coupled receptors by acting as an agonist at opioid receptors 
(Figure 5). Activation of opioid receptors increases dopamine concentrations in the synapse. 
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Dopamine binds to the receptors on the post-synaptic neuron, eliciting a cellular response in the 
reward pathway (Adinoff, B., 2004).  
Morphine Mechanism of Action 
 
Figure 5: Morphine (green) activates opiate receptor, increasing the concentration of dopamine (blue). Dopamine 
then binds to receptors (purple) on post-synaptic neuron (National Institute on Drug Abuse, 2007). 
 
 
Physiological Effects of Opioid Use 
Opioids have a substantial impact on all aspects of the body. The most common 
physiological effect from opioid use is constipation, occurring in 40-95% of users. The activation 
of mu and delta opioid receptors result in decreased GI motility, causing constipation. It can take 
only one dose of opioids to cause constipation. Although constipation seems like a relatively 
minor side effect, chronic constipation can lead to hemorrhoid formation, rectal pain, bowel 
obstruction, potential bowel rupture, as well as significant reduction in quality of life.  
Consistent opioid use suppresses the immune system, which increases HIV risk and 
susceptibility for infections including hepatitis C and tuberculosis (Dennis, B., Naji, L., et al., 
2014). Hormonal changes occur in men and women with chronic opioid use. Men experience 
decreased testosterone, libido, sexual dysfunction, and energy levels. Women may also 
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experience decreased estrogen levels, possibly inducing dysmenorrhea (painful menstrual cycle), 
sexual dysfunction, osteoporosis, and decreased bone mineral density. Interestingly, long term 
use of opioids can induce hyperalgesia, defined as the increased sensitivity to pain. This may be 
related to the enhanced release of excitatory neurotransmitters. Consistent opioid users may also 
reach the point of tolerance, which will reduce medication effectiveness and require ever-
increasing dosage (Benyamin, R., Trescot, A., et al., 2008).  
Mental effects 
Long term opioid use leads to higher incidences of anxiety, depression, and suicide. 
Opioid use is associated with the onset and recurrence of depression, increasing suicide risk. The 
activation of kappa opioid receptors induces hallucinations, dysphoria, overwhelming sense of 
dissatisfaction, anxiety, or restlessness. As the opioid epidemic increases, the rate of suicide 
increases. Suicide was the tenth leading cause of death in 2014 within the United States, which 
increased 20% from 1999.  
Intentional self-poisoning, which accounts for over 5,000 suicides per year, is the most 
common means of poisoning admissions to emergency departments. Prescription opioid use is 
linked to poorly managed pain, which can independently be associated with suicidal thoughts 
and behaviors. When an individual has a poor quality of life, their depression may escalate, 
which increases the risk for suicidal thoughts and attempts. Anxiety disorders are more prevalent 
in chronic pain patients, requiring them to take long-term opioids, increasing the risk of 
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Treatment for Acute Opioid Overdose  
Naloxone 
The medication used for reversal of opioid overdose is Naloxone. Naloxone, commonly 
known as Narcan, is a medication used to rapidly reverse an acute opioid overdose. Naloxone 
acts as an antagonist at opioid receptors, with the highest affinity for the mu receptor. The 
substance acts as an antagonist at the kappa and delta opioid receptors as well, but with lower 
affinity (Adinoff, B., 2004). Narcan quickly returns the users respirations to normal, as they 
likely experienced respiratory depression when the opioid receptors were activated. The FDA-
approved ways for administration of Naloxone are auto injectable and prepackaged nasal spray. 
Evzio is a prefilled auto-injection device that can be administered quickly into the outer thigh of 
the individual. The device provides verbal instructions, similar to an automated defibrillator, 
allowing families or emergency personnel to operate the device with ease.  
Narcan, the most common form of Naloxone used in emergency settings, is a 
prepackaged nasal spray device that allows medication to be sprayed up one nostril as the 
individual is laying on their back. Narcan takes effect quickly, changing the individual’s 
condition from unconscious, to alert and oriented in approximately five minutes. The medication 
lasts approximately 30-90 minutes, but if the person regresses to their unconscious state with 
shallow breathing, additional doses can be administered. After administering Narcan, medical 
personnel should monitor the user for two hours to monitor their breathing. Naloxone is a safe 
drug that only takes effects on individuals with opioid substances in their system (National 
Institute on Drug Abuse-Opioid Overdose Reversal, 2016). 
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Treatment for Opioid Dependence 
Methadone 
Acting as an agonist at the opioid receptors, Methadone has demonstrated positive results 
for 30 years in individual’s dependent on opioids. The molecule binds to the receptors, eliciting 
effects similar, but weaker than opioids, helping suppress opioid withdrawals. Users take a daily 
oral dose of Methadone, while keeping close out-patient follow up with their doctors. A study 
performed by Eric Strain, et al. in 1999 found that a higher dose of Methadone showed a greater 
effect on the patient. The moderate dose range 40 to 50 mg of Methadone daily resulted in less 
detoxification completion compared to the higher dose of 80 to 100 mg daily. Following the 
study, 33% of the higher dose group completed detoxification, compared to 20% completion in 
the lower dose group.  The drug continues to show promise for helping opioid dependence, as it 
has been identified to decrease drug use and transmission of human immunodeficiency virus 
infection (HIV). (Strain, E., Bigelow, G., et al., 1999).  
Suboxone 
Suboxone is a substance composed of two medications, Buprenorphine and Naloxone, in a 4:1 
ratio, respectively. Buprenorphine is classified as a partial opioid agonist, activating the receptor 
with the same characteristics as the prescription or synthetic opioids, but with less strength. 
Naloxone, as stated above, acts as an opioid antagonist, blocking opioids from binding to a 
receptor; there is no neuronal response when Naloxone binds to the receptor. Between the 
combination of Buprenorphine and Naloxone, Suboxone alleviates withdrawal symptoms. The 
medication provides enough opioid receptor activity to avoid withdrawals, but not enough 
stimulation compared to prescription or synthetic opioids. Since Suboxone reduces the activity at 
the opioid receptors, the individual experiences less physical dependence (Dennis, B., Naji, L., et 
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al., 2014) (Damian, A., Mendeson, T., et al, 2017). The difference in activity levels of 
Buprenorphine and Naloxone compared to Heroin are shown below in figure 6.  
Heroin, Buprenorphine, and Naloxone activation 
 
Figure 6: Comparison between Heroin, Buprenorphine, and Naloxone at the receptor (European Monitoring Centre 
for Drugs and Drug Addiction, 2005). 
 
Conclusion 
On October 26, 2017, the opioid epidemic was declared a public health emergency in the 
United States. The opioid epidemic is a serious problem in the United States, with approximately 
60,000 deaths due to overdose in 2016. Naloxone (Narcan) has the potential to save the life of an 
individual who has overdosed on opioids, but that is not the cure for this epidemic. With our 
current knowledge of opioids, researchers are studying additional medications and programs to 
minimize the opioid dependence and use. As the 2017 U.S. General Surgeon Jerome Adams 
states, “There is not one thing we can do to turn this opioid epidemic around, but we want to stop 
the deluge of people who are dying and help these people get connected with care.” In addition 
to the current medications available for opioid dependence and overdose, further treatment 
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options including detoxification programs, prevention, and general knowledge for the public and 
physicians will be the key to reducing the severity of this opioid epidemic.  
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